Gulsah Bayraktar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gulsah Bayraktar has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Huseyin Istanbullu
İzmir Katip Çelebi University, Turkey
6 shared publications - Vildan Alptüzün
Department of Pharmaceutical Chemistry Faculty of Pharmacy, Ege University Izmir Turkey
5 shared publications Ercin Erciyas
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ege University, Bornova, Izmir, Turkey
3 shared publicationsMerve Saylam
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Izmir Katip Celebi University, 35620 Izmir, Turkey
3 shared publications- Pascal Marchand
Nantes Université, Cibles et Médicaments des Infections et de l’Immunité, IICiMed, UR 1155, F-44000 Nantes, France
3 shared publications - Christophe Rochais
Université de Caen Normandie, Normandie Univ., CERMN, 14000, Caen, France
2 shared publications
Latest Publications
- 31 August 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (2) , 503-516
Synthesis and Biological Evaluation of Tacrine Derivatives as Potential Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer’s Disease
Some tacrine derivatives bearing unsubstituted and para-substituted benzylidene moiety linked to the hydrazine function were synthesized and screened for potential acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. They were purified and structurally characterized by FT-IR, 1H NMR, and ESI-MS spectroscopy, confirming the proposed molecular structures. Their inhibitory activities against AChE and BChE were evaluated using a modified Ellman’s colorimetric assay. All compounds exhibited significant inhibitory potency, with IC50 values ranging from 0.088 to 0.359 µM on AChE and from 0.025 to 0.093 µM on BChE. Among the derivatives, compound 1b bearing a methyl substituent on the benzylidene ring showed the highest AChE inhibition (IC50= 0.088 µM), while the unsubstituted derivative 1a exhibited the highest BChE inhibition (IC50= 0.025 µM). Molecular docking studies were also conducted to elucidate the possible binding mode of the most active compounds (1b for AChE; 1a for BChE), and the ADMET properties of all compounds were predicted using the ADME and toxicity tools of the PreADMET website.
- 31 August 2026
- Published by FABAD Farmasotik Bilimler Ankara Dernegi in Fabad Journal of Pharmaceutical Sciences
- Vol. 51 (2) , 503-516
Synthesis and Biological Evaluation of Tacrine Derivatives as Potential Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer’s Disease
Some tacrine derivatives bearing unsubstituted and para-substituted benzylidene moiety linked to the hydrazine function were synthesized and screened for potential acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. They were purified and structurally characterized by FT-IR, 1H NMR, and ESI-MS spectroscopy, confirming the proposed molecular structures. Their inhibitory activities against AChE and BChE were evaluated using a modified Ellman’s colorimetric assay. All compounds exhibited significant inhibitory potency, with IC50 values ranging from 0.088 to 0.359 µM on AChE and from 0.025 to 0.093 µM on BChE. Among the derivatives, compound 1b bearing a methyl substituent on the benzylidene ring showed the highest AChE inhibition (IC50= 0.088 µM), while the unsubstituted derivative 1a exhibited the highest BChE inhibition (IC50= 0.025 µM). Molecular docking studies were also conducted to elucidate the possible binding mode of the most active compounds (1b for AChE; 1a for BChE), and the ADMET properties of all compounds were predicted using the ADME and toxicity tools of the PreADMET website.
- 28 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2045-2047
Shaping Future Medicinal Chemists: Perspectives from European Schools of Pharmacy within the GP2A Network
- 28 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2045-2047
Shaping Future Medicinal Chemists: Perspectives from European Schools of Pharmacy within the GP2A Network
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 24 (28) , 2447-2464
Recent Molecular Targets and their Ligands for the Treatment of Alzheimer Disease
: Alzheimer’s disease is a multifaceted neurodegenerative disease. Cholinergic dysfunction, amyloid β toxicity, tauopathies, oxidative stress, neuroinflammation are among the main pathologies of the disease. Ligands targeting more than one pathology, multi-target directed ligands, attract attention in the recent years to tackle Alzheimer’s disease. In this review, we aimed to cover different biochemical pathways, that are revealed in recent years for the pathology of the disease, as druggable targets such as cannabinoid receptors, matrix metalloproteinases, histone deacetylase and various kinases including, glycogen synthase kinase-3, mitogen-activated protein kinase and c-Jun N-terminal kinase, and their ligands for the treatment of Alzheimer’s disease in the hope of providing more realistic insights into the field.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 24 (28) , 2447-2464
Recent Molecular Targets and their Ligands for the Treatment of Alzheimer Disease
: Alzheimer’s disease is a multifaceted neurodegenerative disease. Cholinergic dysfunction, amyloid β toxicity, tauopathies, oxidative stress, neuroinflammation are among the main pathologies of the disease. Ligands targeting more than one pathology, multi-target directed ligands, attract attention in the recent years to tackle Alzheimer’s disease. In this review, we aimed to cover different biochemical pathways, that are revealed in recent years for the pathology of the disease, as druggable targets such as cannabinoid receptors, matrix metalloproteinases, histone deacetylase and various kinases including, glycogen synthase kinase-3, mitogen-activated protein kinase and c-Jun N-terminal kinase, and their ligands for the treatment of Alzheimer’s disease in the hope of providing more realistic insights into the field.
- Open Access
- 9 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Biological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms
- 9 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry Reports
- Vol. 12
Open AccessBiological properties and in silico studies of thiazolopyrimidine derivatives active against visceral and cutaneous Leishmania spp. amastigote forms
- Open Access
- 9 April 2024
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (7) , e2300575
Novel multifunctional tacrine–donepezil hybrids against Alzheimer's disease: Design synthesis and bioactivity studies
A series of tacrine–donepezil hybrids were synthesized as potential multifunctional anti‐Alzheimer's disease (AD) compounds. For this purpose, tacrine and the benzylpiperidine moiety of donepezil were fused with a hydrazone group to achieve a small library of tacrine–donepezil hybrids. In agreement with the design, all compounds showed inhibitory activity toward both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values in the low micromolar range. Kinetic studies on the most potent cholinesterase (ChE) inhibitors within the series showed a mixed‐type inhibition mechanism on both enzymes. Also, the docking studies indicated that the compounds inhibit ChEs by dual binding site (DBS) interactions. Notably, tacrine–donepezil hybrids also exhibited significant neuroprotection against H2O2‐induced cell death in a differentiated human neuroblastoma (SH‐SY5Y) cell line at concentrations close to their IC50 values on ChEs and showed high to medium blood–brain barrier (BBB) permeability on human cerebral microvascular endothelial cells (HBEC‐5i). Besides, the compounds do not cause remarkable toxicity in a human hepatocellular carcinoma cell line (HepG2) and SH‐SY5Y cells. Additionally, the compounds were predicted to also have good bioavailability. Among the tested compounds, H4, H16, H17, and H24 stand out with their biological profile. Taken together, the proposed novel tacrine–donepezil scaffold represents a promising starting point for the development of novel anti‐ChE multifunctional agents against AD.
- 9 April 2024
- Published by Wiley in Archiv der Pharmazie
- Vol. 357 (7) , e2300575
Open AccessNovel multifunctional tacrine–donepezil hybrids against Alzheimer's disease: Design synthesis and bioactivity studies
A series of tacrine–donepezil hybrids were synthesized as potential multifunctional anti‐Alzheimer's disease (AD) compounds. For this purpose, tacrine and the benzylpiperidine moiety of donepezil were fused with a hydrazone group to achieve a small library of tacrine–donepezil hybrids. In agreement with the design, all compounds showed inhibitory activity toward both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values in the low micromolar range. Kinetic studies on the most potent cholinesterase (ChE) inhibitors within the series showed a mixed‐type inhibition mechanism on both enzymes. Also, the docking studies indicated that the compounds inhibit ChEs by dual binding site (DBS) interactions. Notably, tacrine–donepezil hybrids also exhibited significant neuroprotection against H2O2‐induced cell death in a differentiated human neuroblastoma (SH‐SY5Y) cell line at concentrations close to their IC50 values on ChEs and showed high to medium blood–brain barrier (BBB) permeability on human cerebral microvascular endothelial cells (HBEC‐5i). Besides, the compounds do not cause remarkable toxicity in a human hepatocellular carcinoma cell line (HepG2) and SH‐SY5Y cells. Additionally, the compounds were predicted to also have good bioavailability. Among the tested compounds, H4, H16, H17, and H24 stand out with their biological profile. Taken together, the proposed novel tacrine–donepezil scaffold represents a promising starting point for the development of novel anti‐ChE multifunctional agents against AD.
- Open Access
- 4 January 2023
- Published by IntechOpen
Fused Pyridine Derivatives: Synthesis and Biological Activities
Five-membered heteroaromatic ring fused pyridine derivatives are of increasing interest in drug design and medicinal chemistry. The structural similarity of many drugs (especially antiviral and anticancer ones) with DNA bases such as adenine and guanine is a key factor to explain their effectiveness. Apart from these, it is also found in the structures of substances with antituberculosis, antibacterial, antifungal, anti-inflammatory, and antimalarial activities. Another advantage of this group of compounds is their positive contribution to solubility, polarity, lipophilicity, and hydrogen bonding capacity properties of the compounds they are incorporated into. In this chapter, various bioactivities of fused pyridine derivatives will be categorized and summarized.
- 4 January 2023
- Published by IntechOpen
Open AccessFused Pyridine Derivatives: Synthesis and Biological Activities
Five-membered heteroaromatic ring fused pyridine derivatives are of increasing interest in drug design and medicinal chemistry. The structural similarity of many drugs (especially antiviral and anticancer ones) with DNA bases such as adenine and guanine is a key factor to explain their effectiveness. Apart from these, it is also found in the structures of substances with antituberculosis, antibacterial, antifungal, anti-inflammatory, and antimalarial activities. Another advantage of this group of compounds is their positive contribution to solubility, polarity, lipophilicity, and hydrogen bonding capacity properties of the compounds they are incorporated into. In this chapter, various bioactivities of fused pyridine derivatives will be categorized and summarized.
- Open Access
- 13 April 2022
- Published by IntechOpen
Toward New Antileishmanial Compounds: Molecular Targets for Leishmaniasis Treatment
The leishmaniases are a group of diseases caused by protozoan parasites—Leishmania sp. Leishmaniasis is classified among the 20 neglected diseases by WHO. Although the disease has been known for more than 120 years, the number of drugs used for the treatment is still limited to 5–6. The first-line drugs against leishmaniasis are pentavalent antimonials, which were introduced to the treatment 70 years ago—despite all their side effects. Molecular targets are becoming increasingly important for efficacy and selectivity in postgenomic drug research studies. In this chapter, we have discussed potential therapeutic targets of antileishmanial drug discovery such as pteridine reductase (PTR1), trypanothione reductase (TR), N-myristoyltransferase (NMT), trypanothione synthetase (TryS), IU-nucleoside hydrolase, and topoisomerases, enzymes and their inhibitors reported in the literature.
- 13 April 2022
- Published by IntechOpen
Open AccessToward New Antileishmanial Compounds: Molecular Targets for Leishmaniasis Treatment
The leishmaniases are a group of diseases caused by protozoan parasites—Leishmania sp. Leishmaniasis is classified among the 20 neglected diseases by WHO. Although the disease has been known for more than 120 years, the number of drugs used for the treatment is still limited to 5–6. The first-line drugs against leishmaniasis are pentavalent antimonials, which were introduced to the treatment 70 years ago—despite all their side effects. Molecular targets are becoming increasingly important for efficacy and selectivity in postgenomic drug research studies. In this chapter, we have discussed potential therapeutic targets of antileishmanial drug discovery such as pteridine reductase (PTR1), trypanothione reductase (TR), N-myristoyltransferase (NMT), trypanothione synthetase (TryS), IU-nucleoside hydrolase, and topoisomerases, enzymes and their inhibitors reported in the literature.
- 1 January 2022
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 26(1) (26(1)) , 231-241
Design, Synthesis and Bioactivity Studies of Novel Triazolopyrimidinone Compounds
- 1 January 2022
- Published by Marmara University in Journal of Research in Pharmacy
- Vol. 26(1) (26(1)) , 231-241
Design, Synthesis and Bioactivity Studies of Novel Triazolopyrimidinone Compounds
- Open Access
- 7 December 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (12) , 1278
29th Annual GP2A Medicinal Chemistry Conference
The 29th Annual GP2A (Group for the Promotion of Pharmaceutical chemistry in Academia) Conference was a virtual event this year due to the COVID-19 pandemic and spanned three days from Wednesday 25 to Friday 27 August 2021. The meeting brought together an international delegation of researchers with interests in medicinal chemistry and interfacing disciplines. Abstracts of keynote lectures given by the 10 invited speakers, along with those of the 8 young researcher talks and the 50 flash presentation posters, are included in this report. Like previous editions, the conference was a real success, with high-level scientific discussions on cutting-edge advances in the fields of pharmaceutical chemistry.
- 7 December 2021
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (12) , 1278
Open Access29th Annual GP2A Medicinal Chemistry Conference
The 29th Annual GP2A (Group for the Promotion of Pharmaceutical chemistry in Academia) Conference was a virtual event this year due to the COVID-19 pandemic and spanned three days from Wednesday 25 to Friday 27 August 2021. The meeting brought together an international delegation of researchers with interests in medicinal chemistry and interfacing disciplines. Abstracts of keynote lectures given by the 10 invited speakers, along with those of the 8 young researcher talks and the 50 flash presentation posters, are included in this report. Like previous editions, the conference was a real success, with high-level scientific discussions on cutting-edge advances in the fields of pharmaceutical chemistry.